Cervical cancer remains a significant global health concern, with early detection being key too improved patient outcomes. Now, a new study published in The BMJ suggests a promising, less invasive method for screening could broaden access to preventative care. Researchers in China have demonstrated that HPV testing using menstrual blood is comparably accurate to traditional cervical sample collection, potentially overcoming barriers related to discomfort, privacy, and access to healthcare facilities. The findings could pave the way for wider implementation of cervical cancer screening programs,notably in underserved communities.
A new, non-invasive method for screening for cervical cancer shows promising results, potentially increasing participation in preventative programs. Early detection is crucial for improving outcomes in cervical cancer, a disease that disproportionately affects women globally.
Persistent infection with certain types of human papillomavirus (HPV) is the primary cause of cervical cancer, making HPV testing a vital part of routine screening. However, barriers to traditional screening – including fear of pain, lack of privacy, stigma, and limited access to information – prevent some women from getting tested.
Researchers in China recently evaluated the accuracy of HPV testing using menstrual blood compared to traditional cervical samples collected by healthcare professionals. The goal was to determine if this alternative method could effectively detect high-grade cervical lesions – CIN2+ or CIN3+ – which typically require treatment.
How the Study Was Conducted
The analysis included 3,068 women between the ages of 20 and 54 with regular menstrual cycles. Participants were recruited between September 2021 and January 2025 from four urban and three rural communities in Hubei Province, China. Each woman provided three samples: a menstrual blood sample collected using a “minipad” – a sterile cotton strip attached to a sanitary pad – a cervical sample collected by a clinician for comparison, and an additional cervical sample for laboratory processing.
Participants also had access to a WeChat mobile app called Early Test, where they could view their test results and receive guidance from healthcare professionals. This integration aimed to improve communication and access to care.
The study’s primary measurements were sensitivity and specificity. Sensitivity refers to a test’s ability to correctly identify individuals *with* the disease, while specificity indicates its ability to correctly identify those *without* the disease.
Study Findings
HPV testing of menstrual blood samples collected with the minipad demonstrated a sensitivity of 94.7% for detecting CIN2+ lesions, comparable to the 92.1% sensitivity of clinician-collected cervical samples. These results suggest the menstrual blood test is highly accurate in identifying potential cervical abnormalities.
Specificity was slightly lower for the menstrual blood samples, at 89.1% compared to 90.0% for the cervical samples. However, the difference was minimal.
The negative predictive value – the probability that a person with a negative test result truly does not have the disease – was identical for both methods, at 99.9%. This indicates a very low chance of missing a true negative case with either testing approach.
There were also no significant differences in positive predictive value (9.9% for the minipad and 10.4% for cervical samples) or the rate of referral to colposcopy, which was similar between the two methods.
The authors emphasize that integrating the testing with the mobile app streamlined result communication and patient counseling, which could facilitate wider implementation of this screening method. Improved communication can lead to better patient adherence and follow-up care.
The study has an observational design, and the authors acknowledge certain limitations. Nevertheless, researchers conclude that the data supports using menstrual blood collected with a minipad as a non-invasive and standard alternative for cervical cancer screening.
According to the authors, the findings from this large population study support including HPV testing from menstrual blood in national cervical cancer screening guidelines.
The study was published on Wednesday in The BMJ.
